Vericel Corporation (VCEL) Stock Price & Analysis

Vericel Corporation (VCEL) closed at USD 41.09 on Wednesday, October 28, 2026, down 5.04% on the day. The US market is currently closed; this is not a live price.

The prior close was USD 43.27; the Oct 28, 2026 session ranged USD 40.59–43.5 on volume of 680,183 shares. Market capitalization is $2.10B, with a 52-week range of USD 28.95–49.32 (NGM). Source: Nexqual, retrieved October 29, 2026 at 07:37 UTC.

Also available as compact Markdown for AI agents: nexqual.com/VCEL.md

Key facts (VCEL)

• Last four reported quarters (through Jun 30, 2026): revenue $306M, net income $24.2M (7.9% margin), free cash flow $61.7M (SEC filings).
• Valuation: P/E 86.9x (avg 193.8x at the last 2 fiscal year-ends).
• 1 of 80 tracked superinvestors hold VCEL (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
• Insider open-market sales, last ~7 months: 14 Form 4 filings, $4.6M; 1 not under a Rule 10b5-1 plan ($327K); 9 by opportunistic insiders (0 outside 10b5-1 plans), 1 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 2.13 on a 1–5 scale) (8 analysts), mean target USD 59.71 (range 52–72).
• Total return with dividends: 1Y +17.8% vs S&P 500 +13.6%; 5Y -10.7% vs S&P 500 +79.8%.
• Next earnings: 2026-11-05, EPS estimate USD 0.06, revenue estimate $78.0M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (VCEL)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (VCEL)

P/E 86.9x · P/S 6.9x · P/FCF 34.1x · P/B 5.7x · FCF yield 2.93% · Earnings yield 1.15%

P/E at fiscal year-ends: Dec 2025 113.7x, Dec 2024 273.9x.

Superinvestors (SEC 13F-HR, Q2 2026) (VCEL)

1 of 80 tracked investors hold VCEL. Each row is the investor's latest 13F; change is vs their prior-quarter share count.

Insider sales (SEC Form 4, open-market, last ~7 months) (VCEL)

13 of 14 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (VCEL)

Consensus Buy (mean 2.13 on a 1–5 scale), 8 analysts; mean target USD 59.71 (low 52, high 72).

Rating changes, last 120 days:

Total return (dividends reinvested) (VCEL)

VCEL earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

VCEL recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

VCEL suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 26, 2026.

Companies that name VCEL in their SEC reports

VCEL customer concentration

In the period ended Dec 31, 2025, a single direct customer accounted for 13% of revenue, per the company's 10-K filed Feb 26, 2026. The company does not name it.

VCEL analyst estimates and revisions

VCEL options: expected move

Options price a move of about ±12.9% (±$5.40) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±4.9% on average.

30-day implied volatility 60.2% vs 31.3% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 07:37 UTC)

Technical Analysis (VCEL)

Nexqual's technical model rates VCEL "BUY" based on 4 bullish and 1 bearish signals across 127 daily candles, as of October 29, 2026 at 07:37 UTC.

Analyst Ratings (VCEL)

Wall Street analysts rate VCEL "Buy" based on 8 analysts, with a mean price target of USD 59.71 (range USD 52–72), per Nexqual as of October 29, 2026 at 07:37 UTC.

Earnings (VCEL)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 07:37 UTC.

Financials & Fundamentals (VCEL)

Source: Nexqual, October 29, 2026 at 07:37 UTC.

Financial Health Score (VCEL)

Nexqual rates Vericel Corporation's overall financial health "Solid" across five dimensions, as of October 29, 2026 at 07:37 UTC.

Ownership (VCEL)

Source: Nexqual, October 29, 2026 at 07:37 UTC.

Leadership (VCEL)

Vericel Corporation is led by Dominick C. Colangelo, CEO, President & Director, per Nexqual as of October 29, 2026 at 07:37 UTC.

Major Backers & Investors (VCEL)

Notable institutional backers of Vericel Corporation include Congress Asset Management Co, Conestoga Capital Advisors, LLC, William Blair Investment Management, LLC, according to Nexqual as of October 29, 2026 at 07:37 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 07:37 UTC.

From Vericel Corporation's Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• In August 2024, the FDA approved a supplemental Biologics License Application ("sBLA") expanding the MACI indication to add instructions for the arthroscopic delivery of MACI to the product's approved labeling.
• The FDA regulates biologics under the Federal Food, Drug, and Cosmetic Act ("FFDCA") and the Public Health Service Act ("PHSA"), and their implementing regulations.
• To achieve this objective, we intend to: •Continue to invest in potential MACI growth initiatives; •Seek clinical indication expansion for MACI, including for usage in additional joints; •Launch MACI outside the United States in select markets, including the United Kingdom; •Leverage our unique burn portfolio to expand the number of burn centers and surgeons using Epicel and NexoBrid; and; •Generate positive operating income and cash flow.
• The expanded cells are then uniformly seeded onto a resorbable collagen membrane using a proprietary process prior to shipment.

Partnerships

• MediWound has additionally registered trademarks with respect to NexoBrid, which we have licensed as part of our License Agreement with MediWound.
• On July 1, 2023, we renewed our long-term supply agreement with Matricel GmbH ("Matricel") for the supply of ACI-Maix collagen membranes used in the manufacture of MACI (the "Matricel Supply Agreement").

Legal & Regulatory Risks (Item 1A, quoted)

• The price and sale of any of our products may be limited by health insurance coverage and government regulation.
• We are subject to significant regulation with respect to the manufacturing of our products. If we are not able to comply with such regulation, our business may be materially harmed.
• Our business, financial condition, results of operation and cash flows could be significantly and negatively affected by substantial governmental regulations.
• Any of these consequences, in combination or alone, or even a public announcement that we are being investigated for possible violations of these laws, could have a material adverse effect on our business, financial condition, results of operations and cash flows.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 07:37 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt